10 Best Low Priced Biotech Stocks to Buy Now

2. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Stock Price: $6.99

Number of Hedge Fund Holders: 45

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a clinical-stage biotechnology company that develops gene therapy treatment options targeting rare pediatric diseases. Its clinical program is an LVV-based gene therapy that treats Fanconi Anemia (FA), a difficult-to-treat genetic disease leading to bone marrow failure and even cancer.

On May 9, LifeSci Capital analyst Cory Jubinville, PhD, maintained a bullish stance on Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), giving it a Buy rating due to its strategic positioning in the competitive market and its promising developments.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is actively advancing its RP-A601 program for PKP2-associated arrhythmogenic cardiomyopathy (ACM) in a highly competitive market. Despite the competition, the analyst is bullish on the stock because of its approach that involves a higher starting dose, which may lead to favorable outcomes and more robust protein expression.

In another report released on May 9, J.P. Morgan also maintained a Buy rating on the stock with a $44.00 price target.